Literature DB >> 1870202

Recombinant CD4-selected human immunodeficiency virus type 1 variants with reduced gp120 affinity for CD4 and increased cell fusion capacity.

J McKeating1, P Balfe, P Clapham, R A Weiss.   

Abstract

Variants of molecularly cloned human immunodeficiency virus type 1 (HIV-1) were analyzed following selection for the ability to replicate after exposure to soluble, recombinant CD4 protein (rCD4). Two variants, 4/1 and 16/2, show 8-fold and 16-fold reduced sensitivity to rCD4 neutralization yet remain as sensitive as the parental wild-type (wt) virus to neutralization by rCD4-immunoglobulin G (IgG) chimeric molecules and to inhibition of cellular infection by anti-CD4 antibody. The 4/1 variant is more cytopathic, with faster cell fusion and replication kinetics than the wt virus. The gp120s derived from the 4/1 and 16/2 variants have 3-fold and 30-fold reduced binding affinities to rCD4, respectively. The 4/1 variant exhibits diminished shedding of virion gp120 induced by rCD4. The binding of and neutralization by V3 loop antibodies and other anti-gp120 antibodies is reduced for 4/1 but not for 16/2. Sequence analysis revealed a codon change at amino acid residue 435 in the C4 region of the gp120 of 16/2. This accounts for its rCD4 insensitivity, since the insertion of this mutation in the wt gp120 yields the same phenotype. The 4/1 variant has a codon change in the V3 region of gp120 (amino acid 311), which accounts for its reduced sensitivity to some neutralizing antibodies but not to rCD4. The ready selection of rCD4-resistant variants has obvious relevance for rCD4-based therapeutic stratagems.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1870202      PMCID: PMC248935     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  54 in total

1.  Morphometric analysis of recombinant soluble CD4-mediated release of the envelope glycoprotein gp120 from HIV-1.

Authors:  R Kirsh; T K Hart; H Ellens; J Miller; S A Petteway; D M Lambert; J Leary; P J Bugelski
Journal:  AIDS Res Hum Retroviruses       Date:  1990-10       Impact factor: 2.205

2.  The T4 gene encodes the AIDS virus receptor and is expressed in the immune system and the brain.

Authors:  P J Maddon; A G Dalgleish; J S McDougal; P R Clapham; R A Weiss; R Axel
Journal:  Cell       Date:  1986-11-07       Impact factor: 41.582

3.  Differential loss of envelope glycoprotein gp120 from virions of human immunodeficiency virus type 1 isolates: effects on infectivity and neutralization.

Authors:  J A McKeating; A McKnight; J P Moore
Journal:  J Virol       Date:  1991-02       Impact factor: 5.103

4.  Dissociation of gp120 from HIV-1 virions induced by soluble CD4.

Authors:  J P Moore; J A McKeating; R A Weiss; Q J Sattentau
Journal:  Science       Date:  1990-11-23       Impact factor: 47.728

5.  Poliovirus mutants resistant to neutralization with soluble cell receptors.

Authors:  G Kaplan; D Peters; V R Racaniello
Journal:  Science       Date:  1990-12-14       Impact factor: 47.728

6.  Concurrent evolution of human immunodeficiency virus type 1 in patients infected from the same source: rate of sequence change and low frequency of inactivating mutations.

Authors:  P Balfe; P Simmonds; C A Ludlam; J O Bishop; A J Brown
Journal:  J Virol       Date:  1990-12       Impact factor: 5.103

7.  Soluble CD4 enhances simian immunodeficiency virus SIVagm infection.

Authors:  A Werner; G Winskowsky; R Kurth
Journal:  J Virol       Date:  1990-12       Impact factor: 5.103

8.  Conformational epitope on gp120 important in CD4 binding and human immunodeficiency virus type 1 neutralization identified by a human monoclonal antibody.

Authors:  D D Ho; J A McKeating; X L Li; T Moudgil; E S Daar; N C Sun; J E Robinson
Journal:  J Virol       Date:  1991-01       Impact factor: 5.103

9.  Direct measurement of soluble CD4 binding to human immunodeficiency virus type 1 virions: gp120 dissociation and its implications for virus-cell binding and fusion reactions and their neutralization by soluble CD4.

Authors:  J P Moore; J A McKeating; W A Norton; Q J Sattentau
Journal:  J Virol       Date:  1991-03       Impact factor: 5.103

10.  Novel anti-CD4 monoclonal antibodies separate human immunodeficiency virus infection and fusion of CD4+ cells from virus binding.

Authors:  D Healey; L Dianda; J P Moore; J S McDougal; M J Moore; P Estess; D Buck; P D Kwong; P C Beverley; Q J Sattentau
Journal:  J Exp Med       Date:  1990-10-01       Impact factor: 14.307

View more
  20 in total

1.  Human immunodeficiency virus type 2 infection and fusion of CD4-negative human cell lines: induction and enhancement by soluble CD4.

Authors:  P R Clapham; A McKnight; R A Weiss
Journal:  J Virol       Date:  1992-06       Impact factor: 5.103

2.  Resistance of a human serum-selected human immunodeficiency virus type 1 escape mutant to neutralization by CD4 binding site monoclonal antibodies is conferred by a single amino acid change in gp120.

Authors:  J A McKeating; J Bennett; S Zolla-Pazner; M Schutten; S Ashelford; A L Brown; P Balfe
Journal:  J Virol       Date:  1993-09       Impact factor: 5.103

3.  Virions of primary human immunodeficiency virus type 1 isolates resistant to soluble CD4 (sCD4) neutralization differ in sCD4 binding and glycoprotein gp120 retention from sCD4-sensitive isolates.

Authors:  J P Moore; J A McKeating; Y X Huang; A Ashkenazi; D D Ho
Journal:  J Virol       Date:  1992-01       Impact factor: 5.103

4.  Identification of key residues in subgroup A avian leukosis virus envelope determining receptor binding affinity and infectivity of cells expressing chicken or quail Tva receptor.

Authors:  S L Holmen; D C Melder; M J Federspiel
Journal:  J Virol       Date:  2001-01       Impact factor: 5.103

5.  Initial appearance of the 184Ile variant in lamivudine-treated patients is caused by the mutational bias of human immunodeficiency virus type 1 reverse transcriptase.

Authors:  W Keulen; N K Back; A van Wijk; C A Boucher; B Berkhout
Journal:  J Virol       Date:  1997-04       Impact factor: 5.103

6.  Association of T cell and macrophage dysfunction with surface gp 120-immunoglobulin-complement complexes in HIV-infected patients.

Authors:  V Daniel; C Süsal; R Weimer; R Zimmermann; A Huth-Kühne; G Opelz
Journal:  Clin Exp Immunol       Date:  1993-08       Impact factor: 4.330

7.  Characterization of neutralizing monoclonal antibodies to linear and conformation-dependent epitopes within the first and second variable domains of human immunodeficiency virus type 1 gp120.

Authors:  J A McKeating; C Shotton; J Cordell; S Graham; P Balfe; N Sullivan; M Charles; M Page; A Bolmstedt; S Olofsson
Journal:  J Virol       Date:  1993-08       Impact factor: 5.103

8.  Strain specificity and binding affinity requirements of neutralizing monoclonal antibodies to the C4 domain of gp120 from human immunodeficiency virus type 1.

Authors:  G R Nakamura; R Byrn; D M Wilkes; J A Fox; M R Hobbs; R Hastings; H C Wessling; M A Norcross; B M Fendly; P W Berman
Journal:  J Virol       Date:  1993-10       Impact factor: 5.103

9.  Two mechanisms of soluble CD4 (sCD4)-mediated inhibition of human immunodeficiency virus type 1 (HIV-1) infectivity and their relation to primary HIV-1 isolates with reduced sensitivity to sCD4.

Authors:  S L Orloff; M S Kennedy; A A Belperron; P J Maddon; J S McDougal
Journal:  J Virol       Date:  1993-03       Impact factor: 5.103

10.  Identification of an N-linked glycan in the V1-loop of HIV-1 gp120 influencing neutralization by anti-V3 antibodies and soluble CD4.

Authors:  G J Gram; A Hemming; A Bolmstedt; B Jansson; S Olofsson; L Akerblom; J O Nielsen; J E Hansen
Journal:  Arch Virol       Date:  1994       Impact factor: 2.574

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.